Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PHARMACEUTICAL BASICS' TIMOLOL MALEATE IS FIRST ANDA APPROVAL

Executive Summary

PHARMACEUTICAL BASICS' TIMOLOL MALEATE IS FIRST ANDA APPROVAL for a generic version of Merck's beta blocker Blocadren. The Pharmaceutical Basics Inc. (PBI) timolol ANDA was approved in 5 mg, 10 mg and 20 mg strengths on Jan. 10. The approval is effectively delayed until April 11, when Merck's patent for timolol expires. The timolol patent is also the effective patent for Merck's ophthalmic product Timoptic, which controls a much larger market than the heart drug Blocadren. Analyst estimates for Timoptic sales in the U.S. are in the $100-110 mil. range, while Blocadren sales are estimated in the $15-20 mil. range. On Jan. 11, FDA approved Danbury's ANDA for prazosin - the second generic version of Pfizer's Minipress (prazosin). Zenith received an ANDA approval for prazosin in September. Marketing of prazosin is delayed until May 16, 1989, according to FDA's "Orange Book."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest News
See All
UsernamePublicRestriction

Register

PS014954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel